(Q37382793)

20 August 2017

1 reference

title

Emergency surgery in the era of molecular treatment of solid tumours (English)

1 reference

20 August 2017

1

Piotr Rutkowski

1 reference

20 August 2017

2

Włodzimierz Ruka

1 reference

PubMed ID

19185833

20 August 2017

language of work or name

1 reference

1 February 2009

1 reference

Lancet Oncology Commission

20 August 2017

1 reference

20 August 2017

10

1 reference

20 August 2017

157-163

1 reference

20 August 2017

2

1 reference

Review: side effects of approved molecular targeted therapies in solid cancers.

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Gastrointestinal perforation due to bevacizumab in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Incidence and management of bevacizumab-related toxicities in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

The potential of antiangiogenic therapy in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Targeted therapies in lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

SU5416 delays wound healing through inhibition of TGF-beta 1 activation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Clinical implications of mutational analysis in gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Biology of gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Gastrointestinal stromal tumors (GIST)--current concepts of surgical management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Surgical resection of gastrointestinal stromal tumors after treatment with imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Intraperitoneal hemorrhage from hepatocellular carcinoma: emergency chemoembolization or embolization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Life-saving therapy for haemorrhaging liver adenomas using selective arterial embolization.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

Non-operative management of arterial liver hemorrhages

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970017-8

7 January 2021

10.1016/S1470-2045(09)70017-8

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19185833